Additionally, two phase 3 trials (COMBI-d and COMBI-v) demonstrated improved effects of the combination of BRAF (dabrafenib) and MEK (trametinib) inhibitors compared to monotherapy BRAF inhibition for advanced melanoma [10,11]. This evidence concerns the gene MAP2K7 and melanoma.